Please login to the form below

Not currently logged in
Email:
Password:

J&J appoints quality-control chief

Johnson & Johnson has created a new position at the company to oversee all quality, manufacturing and compliance issues 

In the wake of a series of major recalls of its nonprescription medicines, Johnson & Johnson (J&J) has created a new position at the company to oversee all quality, manufacturing and compliance issues.

Ajit Shetty, who is chairman of the board and managing director of the J&J subsidiary Janssen Pharmaceutica, has been tapped to fill the new post. He will serve as a corporate vice president of J&J, reporting directly to company CEO William Weldon, and will oversee quality improvement efforts for J&J's pharmaceutical, consumer products, medical device and diagnostics groups.

Shetty has been with J&J since 1976. He was raised in India but holds an MBA from Carnegie Mellon University in the US, as well as a PhD from Trinity College/Cambridge University in the UK.

In addition, J&J said it has appointed chief quality officers for each of its three major business units. Those positions will report to Shetty.

The recalls, which caused a PR crisis for J&J, involved Children's Tylenol, Motrin and St Joseph aspirin, the allergy drug Benadryl, the antacid Rolaids and Simply Sleep pills.

The products were manufactured at a Pennsylvania factory that has been temporarily shuttered, as well as at another facility in Puerto Rico. Some products were contaminated with bacteria, while others were made with the wrong amount of active ingredient, and still others contained metal shavings.

19th August 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Frontera Group

Welcome to Frontera Group, where our agencies immerse you in the world of the patient...

Latest intelligence

Harness the power of data to map new patient pathways
Oli Hudson, of Wilmington Healthcare, explains why pharma needs to put data at the heart of its bid to support the NHS Reset...
What NORD’s RareInsights® 30-year comparative analysis means to us and our clients at OPEN Health
...
Peter Jackson
Rethinking our approach to infectious disease preparedness
The importance of long-term strategic investment to prepare for the next threat that emerges...

Infographics